Gsa Capital Partners LLP Protalix Bio Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.43 Billion
- Q2 2024
A detailed history of Gsa Capital Partners LLP transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 401,244 shares of PLX stock, worth $421,306. This represents 0.03% of its overall portfolio holdings.
Number of Shares
401,244
Previous 493,571
18.71%
Holding current value
$421,306
Previous $621,000
24.48%
% of portfolio
0.03%
Previous 0.05%
Shares
9 transactions
Others Institutions Holding PLX
# of Institutions
70Shares Held
5.61MCall Options Held
103KPut Options Held
4.6K-
Israel Englander Millennium Management LLC | New York, Ny811KShares$851,7180.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny805KShares$844,8300.0% of portfolio
-
Goldman Sachs Group Inc New York, NY462KShares$485,0550.0% of portfolio
-
Northern Trust Corp Chicago, IL423KShares$444,3730.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$349,8290.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $52.2M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...